BE905209A - Farmaceutisch preparaat bevattend ubichinon,voor orale toediening. - Google Patents
Farmaceutisch preparaat bevattend ubichinon,voor orale toediening. Download PDFInfo
- Publication number
- BE905209A BE905209A BE2/61024A BE2061024A BE905209A BE 905209 A BE905209 A BE 905209A BE 2/61024 A BE2/61024 A BE 2/61024A BE 2061024 A BE2061024 A BE 2061024A BE 905209 A BE905209 A BE 905209A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- coenzyme
- yeast extract
- pharmaceutical preparations
- dry
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 13
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 45
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 41
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 28
- 239000012138 yeast extract Substances 0.000 claims abstract description 28
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229940035936 ubiquinone Drugs 0.000 claims abstract description 4
- 230000009758 senescence Effects 0.000 claims abstract description 3
- 206010049565 Muscle fatigue Diseases 0.000 claims abstract 2
- 230000001771 impaired effect Effects 0.000 claims abstract 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 25
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 25
- 239000005515 coenzyme Substances 0.000 claims description 18
- 238000010521 absorption reaction Methods 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 150000003669 ubiquinones Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims 2
- 206010056697 Tissue anoxia Diseases 0.000 claims 1
- 239000008298 dragée Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 10
- 229940088594 vitamin Drugs 0.000 description 10
- 229930003231 vitamin Natural products 0.000 description 10
- 235000013343 vitamin Nutrition 0.000 description 10
- 239000011782 vitamin Substances 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 9
- 150000003722 vitamin derivatives Chemical class 0.000 description 8
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000002107 myocardial effect Effects 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 229940046001 vitamin b complex Drugs 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 241000976983 Anoxia Species 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002438 mitochondrial effect Effects 0.000 description 3
- 230000010627 oxidative phosphorylation Effects 0.000 description 3
- 229940072644 pitressin Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000002407 ATP formation Effects 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FTYKMBHMBMJVFG-UHFFFAOYSA-N 5'-Phosphate-beta-D-9-Ribofuranosyluric acid Natural products COC1=C(OC)C(=O)C(=C(C)C1=O)CC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCC=C(/C)CCCC(C)C FTYKMBHMBMJVFG-UHFFFAOYSA-N 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CZXMBEXHCFIYPB-UHFFFAOYSA-N Coenzym Q Natural products OC(=O)CCCC1CCC(CC(O)=O)O1 CZXMBEXHCFIYPB-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 108010067035 Pancrelipase Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940031192 coenzyme Q10 10 mg Drugs 0.000 description 1
- 229940019909 coenzyme Q10 100 mg Drugs 0.000 description 1
- 229940019899 coenzyme Q10 50 mg Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- -1 etc.) and nucleins Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- SOECUQMRSRVZQQ-UHFFFAOYSA-N ubiquinone-1 Chemical compound COC1=C(OC)C(=O)C(CC=C(C)C)=C(C)C1=O SOECUQMRSRVZQQ-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940023356 vitamin b6 10 mg Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH3363/85A CH666184A5 (it) | 1985-08-06 | 1985-08-06 | Composizione farmaceutica orale a base di ubichinoni. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE905209A true BE905209A (nl) | 1986-12-01 |
Family
ID=4254356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2/61024A BE905209A (nl) | 1985-08-06 | 1986-08-04 | Farmaceutisch preparaat bevattend ubichinon,voor orale toediening. |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JPS6259208A (enrdf_load_stackoverflow) |
| BE (1) | BE905209A (enrdf_load_stackoverflow) |
| CH (1) | CH666184A5 (enrdf_load_stackoverflow) |
| DE (1) | DE3625459A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2585953B1 (enrdf_load_stackoverflow) |
| GB (1) | GB2178662B (enrdf_load_stackoverflow) |
| IT (1) | IT1213320B (enrdf_load_stackoverflow) |
| NL (1) | NL8601978A (enrdf_load_stackoverflow) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8703321D0 (sv) * | 1987-08-27 | 1987-08-27 | Sockerbolaget Ab | Kostforsterkning |
| DE9402223U1 (de) * | 1994-01-20 | 1994-04-14 | Latta Bernd | Flüssige Mixtur zur inneren Anwendung für den vorbeugenden Gesundheitsschutz |
| JP2005053923A (ja) * | 2000-04-12 | 2005-03-03 | Nisshin Pharma Inc | 安定化されたユビデカレノン組成物およびユビデカレノン組成物の安定化方法 |
| US6806069B2 (en) * | 2001-01-09 | 2004-10-19 | Pharmachem Laboratories, Inc. | Ubiquinone composition and methods related thereto |
| US7708990B2 (en) | 2004-03-23 | 2010-05-04 | Kaneka Corporation | Coenzyme Q compositions persisting in blood |
| TW200603786A (en) | 2004-05-11 | 2006-02-01 | Kaneka Corp | Anti-fatigue composition |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5933354B2 (ja) * | 1976-09-14 | 1984-08-15 | 鐘淵化学工業株式会社 | 補酵素ｑの製造法 |
| EP0106309A3 (de) * | 1982-10-12 | 1986-12-30 | Kailash Kumar Dr. Prof. Gauri | Biologisch aktive Extrakte, Verfahren zu deren Herstellung, sie enthaltende pharmazeutische und kosmetische Mittel und ihre Verwendung als Zusätze für Lebens- und Genussmittel |
| FR2536996B1 (fr) * | 1982-12-01 | 1985-09-27 | Grimberg Georges | Association permettant d'ameliorer l'absorption de divers cations par l'organisme |
| CH654210A5 (it) * | 1983-05-20 | 1986-02-14 | Hasunor Ag | Procedimento per ottenere preparati metabolicamente attivi ottenuti da lievito di qualsiasi tipo. |
-
1985
- 1985-08-06 CH CH3363/85A patent/CH666184A5/it not_active IP Right Cessation
-
1986
- 1986-07-28 DE DE19863625459 patent/DE3625459A1/de active Granted
- 1986-07-30 GB GB8618590A patent/GB2178662B/en not_active Expired
- 1986-08-01 IT IT8621395A patent/IT1213320B/it active
- 1986-08-01 NL NL8601978A patent/NL8601978A/nl not_active Application Discontinuation
- 1986-08-04 BE BE2/61024A patent/BE905209A/nl not_active IP Right Cessation
- 1986-08-05 JP JP61184972A patent/JPS6259208A/ja active Granted
- 1986-08-06 FR FR868611376A patent/FR2585953B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE3625459A1 (de) | 1987-02-19 |
| IT1213320B (it) | 1989-12-20 |
| JPH0380771B2 (enrdf_load_stackoverflow) | 1991-12-26 |
| FR2585953B1 (fr) | 1989-07-07 |
| NL8601978A (nl) | 1987-03-02 |
| CH666184A5 (it) | 1988-07-15 |
| GB2178662B (en) | 1989-09-06 |
| GB8618590D0 (en) | 1986-09-10 |
| GB2178662A (en) | 1987-02-18 |
| IT8621395A0 (it) | 1986-08-01 |
| DE3625459C2 (enrdf_load_stackoverflow) | 1992-03-26 |
| JPS6259208A (ja) | 1987-03-14 |
| FR2585953A1 (fr) | 1987-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Swaroop et al. | Benefits of chromium (III) complexes in animal and human health | |
| EP3873442B1 (en) | A composition for weigth loss or weight management comprising beta-hydroxybutyrate and cannabidiol | |
| Kato et al. | Role of xanthine oxidase in ethanol-induced lipid peroxidation in rats | |
| EP2512236B1 (en) | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
| CN101610769A (zh) | 用于预防和治疗酒精诱导性脂肪肝和脂肪性肝炎的包括美他多辛和大蒜油的医药组合物 | |
| US20050271754A1 (en) | Composition for prevention or treatment of an alcohol hangover | |
| JP2004534094A (ja) | 二日酔いに有効な組成物及びそのための使用 | |
| BE905209A (nl) | Farmaceutisch preparaat bevattend ubichinon,voor orale toediening. | |
| AU750645B2 (en) | Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH | |
| US20040028668A1 (en) | Food supplement with a slimming effect | |
| Gupta et al. | Clinical research and therapeutic importance of dietary supplement L-carnitine | |
| Arends et al. | Influence of physical exercise on the pharmacokinetics of propranolol | |
| US5389359A (en) | Pharmaceutical preparation containing L-aspartate or L-asparagine for preventing ethanol toxicity, and process for preparation thereof | |
| CN101331950A (zh) | 一种提高运动爆发力的营养补剂 | |
| AU719906B2 (en) | Use of L-carnitine and derivatives for reducing ceramide levels and potentiating antiretroviral | |
| JP2022552311A (ja) | 改善した二日酔い止め組成物、その調製及び使用 | |
| JPH07330593A (ja) | 疲労改善剤 | |
| RU2146529C1 (ru) | Набор антиалкогольных средств | |
| Haber | The effect of hydroxylamine and aminooxyacetic acid on the cerebral in vitro utilization of glucose, fructose, glutamic acid, and γ-aminobutyric acid | |
| CN111265514A (zh) | *酮类化合物用于治疗脂肪肝的应用 | |
| KR20200012306A (ko) | 잣잎, 삼백초 및 구기자의 복합 추출물을 함유하는 간 질환 예방 및 치료용 약학 조성물 | |
| KR100309715B1 (ko) | 구연산회로를활성화시켜알코홀독성과숙취를예방하는기능을가지는조성물 | |
| Osibemhe et al. | Sub-chronic toxicity of extracts of Strophanthus hispidus stem bark in normal rats | |
| Dewi et al. | Ergogenic Aid by Cordyceps: Does It Work?? | |
| Kreider et al. | Creatine: The ergogenic/anabolic supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE20 | Patent expired |
Owner name: *HUMAN PHARMA G.M.B.H. & CO. KG Effective date: 20060804 |